Cargando…

SUN-556 Cardiac Phenotype in Familial Partial Lipodystrophy

Background Pathogenic variants in Lamin A/C (LMNA) gene are the most common monogenic etiology in Familial Partial Lipodystrophy (FPLD) causing FPLD2. LMNA pathogenic variants have been previously associated with cardiomyopathy, familial arrhythmias or conduction system abnormalities independent of...

Descripción completa

Detalles Bibliográficos
Autores principales: Eldin, Abdelwahab Jalal, Akinci, Baris, da Rocha, Andre Monteiro, Meral, Rasimcan, Simsir, Ilgin Yildirim, Adiyaman, Suleyman Cem, Ozpelit, Ebru, Bhave, Nicole, Gen, Ramazan, Yurekli, Banu Sarer, Kutbay, Nilufer Ozdemir, Siklar, Zeynep, Neidert, Adam, Swaidan, Mario, Rus, Diana, Hench, Rita, Jalife, Jose, Oral, Hakan, Oral, Elif A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207313/
http://dx.doi.org/10.1210/jendso/bvaa046.1116
_version_ 1783530575548645376
author Eldin, Abdelwahab Jalal
Akinci, Baris
da Rocha, Andre Monteiro
Meral, Rasimcan
Simsir, Ilgin Yildirim
Adiyaman, Suleyman Cem
Ozpelit, Ebru
Bhave, Nicole
Gen, Ramazan
Yurekli, Banu Sarer
Kutbay, Nilufer Ozdemir
Siklar, Zeynep
Neidert, Adam
Swaidan, Mario
Rus, Diana
Hench, Rita
Jalife, Jose
Oral, Hakan
Oral, Elif A
author_facet Eldin, Abdelwahab Jalal
Akinci, Baris
da Rocha, Andre Monteiro
Meral, Rasimcan
Simsir, Ilgin Yildirim
Adiyaman, Suleyman Cem
Ozpelit, Ebru
Bhave, Nicole
Gen, Ramazan
Yurekli, Banu Sarer
Kutbay, Nilufer Ozdemir
Siklar, Zeynep
Neidert, Adam
Swaidan, Mario
Rus, Diana
Hench, Rita
Jalife, Jose
Oral, Hakan
Oral, Elif A
author_sort Eldin, Abdelwahab Jalal
collection PubMed
description Background Pathogenic variants in Lamin A/C (LMNA) gene are the most common monogenic etiology in Familial Partial Lipodystrophy (FPLD) causing FPLD2. LMNA pathogenic variants have been previously associated with cardiomyopathy, familial arrhythmias or conduction system abnormalities independent of lipodystrophy. We aimed to assess cardiac impacts of FPLD, and to explore the extent of overlap between cardiolaminopathies and FPLD. Methods We conducted a retrospective review of an established cohort of 122 patients (age range: 13-77, M/F 21/101) with FPLD from Michigan (n = 83) and Turkey (n = 39) with an accessible cardiac evaluation. Also, functional syncytia of mature human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) from a FLPD2 patient was studied for assessment of autonomous rhythm and action potential duration with optical mapping using a voltage sensitive dye. Results In the whole study cohort, 95 (78%) patients had cardiac alterations (25% ischemic heart disease, 36% arrhythmia, 16% conduction abnormality, 20% prolonged QT interval, 11% cardiomyopathy, and 15% congestive heart failure). The likelihood of having an arrhythmia (OR; 3.95, 95% CI: 1.49-10.49) and conduction disease (OR: 3.324, 95% CI: 1.33-8.31) was significantly higher in patients with LMNA pathogenic variants. Patients with LMNA pathogenic variants were at high risk for atrial fibrillation/flutter (OR: 6.77, 95% CI: 1.27- 39.18). The time to first arrhythmia was significantly shorter in the LMNA group with a higher hazard rate of 3.04 (95% CI: 1.29-7.17, p = 0.032). Non-482 LMNA pathogenic variants were more likely to be associated with cardiac events (vs. 482 LMNA: OR: 4.74, 95% CI: 1.41- 15.98 for arrhythmia; OR: 17.67, 95% CI: 2.44- 127.68 for atrial fibrillation/flutter; OR: 5.71, 95% CI: 1.37- 23.76 for conduction disease. hiPSC-CMs from a FPLD2 patient had higher frequency of autonomous activity, and shorter Fridericia corrected action potential duration at 80% repolarization compared to control cardiomyocytes. Furthermore, FPLD2 functional syncytia of mature hiPSC-CMs presented several rhythm alterations such as early after-depolarizations, spontaneous quiescence and spontaneous tachyarrhythmia; none of those were observed in the control cell lines. Finally, FPLD2 hiPSC-CMs presented significantly slower recovery in chronotropic changes induced by isoproterenol exposure; which indicates disrupted beta-adrenergic response. Conclusion Our results suggest the need for vigilant cardiac monitoring in FPLD, especially in patients with FPLD2 who have an increased risk to develop cardiac arrhythmias and conduction system diseases. In addition, study of human induced pluripotent stem cell-derived cardiomyocytes may prove useful to understand the mechanism of cardiac disease and arrhythmias and to create precision therapy opportunities in the future.
format Online
Article
Text
id pubmed-7207313
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72073132020-05-12 SUN-556 Cardiac Phenotype in Familial Partial Lipodystrophy Eldin, Abdelwahab Jalal Akinci, Baris da Rocha, Andre Monteiro Meral, Rasimcan Simsir, Ilgin Yildirim Adiyaman, Suleyman Cem Ozpelit, Ebru Bhave, Nicole Gen, Ramazan Yurekli, Banu Sarer Kutbay, Nilufer Ozdemir Siklar, Zeynep Neidert, Adam Swaidan, Mario Rus, Diana Hench, Rita Jalife, Jose Oral, Hakan Oral, Elif A J Endocr Soc Cardiovascular Endocrinology Background Pathogenic variants in Lamin A/C (LMNA) gene are the most common monogenic etiology in Familial Partial Lipodystrophy (FPLD) causing FPLD2. LMNA pathogenic variants have been previously associated with cardiomyopathy, familial arrhythmias or conduction system abnormalities independent of lipodystrophy. We aimed to assess cardiac impacts of FPLD, and to explore the extent of overlap between cardiolaminopathies and FPLD. Methods We conducted a retrospective review of an established cohort of 122 patients (age range: 13-77, M/F 21/101) with FPLD from Michigan (n = 83) and Turkey (n = 39) with an accessible cardiac evaluation. Also, functional syncytia of mature human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) from a FLPD2 patient was studied for assessment of autonomous rhythm and action potential duration with optical mapping using a voltage sensitive dye. Results In the whole study cohort, 95 (78%) patients had cardiac alterations (25% ischemic heart disease, 36% arrhythmia, 16% conduction abnormality, 20% prolonged QT interval, 11% cardiomyopathy, and 15% congestive heart failure). The likelihood of having an arrhythmia (OR; 3.95, 95% CI: 1.49-10.49) and conduction disease (OR: 3.324, 95% CI: 1.33-8.31) was significantly higher in patients with LMNA pathogenic variants. Patients with LMNA pathogenic variants were at high risk for atrial fibrillation/flutter (OR: 6.77, 95% CI: 1.27- 39.18). The time to first arrhythmia was significantly shorter in the LMNA group with a higher hazard rate of 3.04 (95% CI: 1.29-7.17, p = 0.032). Non-482 LMNA pathogenic variants were more likely to be associated with cardiac events (vs. 482 LMNA: OR: 4.74, 95% CI: 1.41- 15.98 for arrhythmia; OR: 17.67, 95% CI: 2.44- 127.68 for atrial fibrillation/flutter; OR: 5.71, 95% CI: 1.37- 23.76 for conduction disease. hiPSC-CMs from a FPLD2 patient had higher frequency of autonomous activity, and shorter Fridericia corrected action potential duration at 80% repolarization compared to control cardiomyocytes. Furthermore, FPLD2 functional syncytia of mature hiPSC-CMs presented several rhythm alterations such as early after-depolarizations, spontaneous quiescence and spontaneous tachyarrhythmia; none of those were observed in the control cell lines. Finally, FPLD2 hiPSC-CMs presented significantly slower recovery in chronotropic changes induced by isoproterenol exposure; which indicates disrupted beta-adrenergic response. Conclusion Our results suggest the need for vigilant cardiac monitoring in FPLD, especially in patients with FPLD2 who have an increased risk to develop cardiac arrhythmias and conduction system diseases. In addition, study of human induced pluripotent stem cell-derived cardiomyocytes may prove useful to understand the mechanism of cardiac disease and arrhythmias and to create precision therapy opportunities in the future. Oxford University Press 2020-05-08 /pmc/articles/PMC7207313/ http://dx.doi.org/10.1210/jendso/bvaa046.1116 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Cardiovascular Endocrinology
Eldin, Abdelwahab Jalal
Akinci, Baris
da Rocha, Andre Monteiro
Meral, Rasimcan
Simsir, Ilgin Yildirim
Adiyaman, Suleyman Cem
Ozpelit, Ebru
Bhave, Nicole
Gen, Ramazan
Yurekli, Banu Sarer
Kutbay, Nilufer Ozdemir
Siklar, Zeynep
Neidert, Adam
Swaidan, Mario
Rus, Diana
Hench, Rita
Jalife, Jose
Oral, Hakan
Oral, Elif A
SUN-556 Cardiac Phenotype in Familial Partial Lipodystrophy
title SUN-556 Cardiac Phenotype in Familial Partial Lipodystrophy
title_full SUN-556 Cardiac Phenotype in Familial Partial Lipodystrophy
title_fullStr SUN-556 Cardiac Phenotype in Familial Partial Lipodystrophy
title_full_unstemmed SUN-556 Cardiac Phenotype in Familial Partial Lipodystrophy
title_short SUN-556 Cardiac Phenotype in Familial Partial Lipodystrophy
title_sort sun-556 cardiac phenotype in familial partial lipodystrophy
topic Cardiovascular Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207313/
http://dx.doi.org/10.1210/jendso/bvaa046.1116
work_keys_str_mv AT eldinabdelwahabjalal sun556cardiacphenotypeinfamilialpartiallipodystrophy
AT akincibaris sun556cardiacphenotypeinfamilialpartiallipodystrophy
AT darochaandremonteiro sun556cardiacphenotypeinfamilialpartiallipodystrophy
AT meralrasimcan sun556cardiacphenotypeinfamilialpartiallipodystrophy
AT simsirilginyildirim sun556cardiacphenotypeinfamilialpartiallipodystrophy
AT adiyamansuleymancem sun556cardiacphenotypeinfamilialpartiallipodystrophy
AT ozpelitebru sun556cardiacphenotypeinfamilialpartiallipodystrophy
AT bhavenicole sun556cardiacphenotypeinfamilialpartiallipodystrophy
AT genramazan sun556cardiacphenotypeinfamilialpartiallipodystrophy
AT yureklibanusarer sun556cardiacphenotypeinfamilialpartiallipodystrophy
AT kutbayniluferozdemir sun556cardiacphenotypeinfamilialpartiallipodystrophy
AT siklarzeynep sun556cardiacphenotypeinfamilialpartiallipodystrophy
AT neidertadam sun556cardiacphenotypeinfamilialpartiallipodystrophy
AT swaidanmario sun556cardiacphenotypeinfamilialpartiallipodystrophy
AT rusdiana sun556cardiacphenotypeinfamilialpartiallipodystrophy
AT henchrita sun556cardiacphenotypeinfamilialpartiallipodystrophy
AT jalifejose sun556cardiacphenotypeinfamilialpartiallipodystrophy
AT oralhakan sun556cardiacphenotypeinfamilialpartiallipodystrophy
AT oralelifa sun556cardiacphenotypeinfamilialpartiallipodystrophy